Affinage

PSMB8

Proteasome subunit beta type-8 · UniProt P28062

Length
276 aa
Mass
30.4 kDa
Annotated
2026-06-10
100 papers in source corpus 35 papers cited in narrative 35 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PSMB8 (LMP7/β5i) is the IFN-γ-inducible catalytic subunit of the 20S immunoproteasome, where its active-site threonine confers chymotrypsin-like and contributes to trypsin-like peptide-bond cleavage (PMID:7937744, PMID:9312091). Its yeast ortholog PRE2 is the proteasomal subunit responsible for chymotryptic activity, loss of which abolishes that activity and causes accumulation of ubiquitinated proteins (PMID:8383129). PSMB8 is synthesized as a ~30 kDa proprotein whose N-terminal pro-sequence is cleaved within 13–16S precursor complexes to yield the mature 23 kDa subunit incorporated into the 20S ring, with the propeptide acting as a more efficient maturation chaperone than the constitutive β5 propeptide and POMP restricted to precursor intermediates (PMID:8365398, PMID:8458375, PMID:8120905, PMID:10926487, PMID:22768135). Upon IFN-γ induction—driven transcriptionally by IRF-1—PSMB8 replaces the constitutive subunit X/β5c, shifting cleavage preference toward hydrophobic and basic C-termini and altering the quality of peptide products to optimize generation of MHC class I antigenic peptides (PMID:8663318, PMID:15907481, PMID:7589133, PMID:7559557, PMID:10878350). This antigen-processing role extends to shaping T cell selection in radioresistant thymic cells (PMID:29067678). Beyond antigen presentation, PSMB8 controls inflammatory signaling: its activity sustains NF-κB activation and skews CD4 T cell differentiation toward Th1/Th17 over Treg by modulating STAT3, STAT1, and SMAD phosphorylation (PMID:20581238, PMID:22984077). In cardiovascular and metabolic disease, PSMB8 targets specific substrates for degradation—ATG5 to suppress autophagy and drive cardiac hypertrophy, ATRAP to potentiate AT1R signaling in atrial fibrillation and hypertensive retinopathy, PTEN in hypertensive cardiac remodeling, and MERTK (via NF-κB) to impair efferocytosis in atherosclerosis (PMID:31086810, PMID:30571551, PMID:31636038, PMID:31629736, PMID:31758542). Causative PSMB8 mutations that disrupt β5i structure and immunoproteasome assembly/activity (Thr75Met in JMP syndrome; G201V in Nakajo-Nishimura syndrome; G197V) produce autoinflammatory syndromes with accumulation of ubiquitinated proteins and elevated proinflammatory cytokines (PMID:21129723, PMID:21852578, PMID:21881205). Structure-based design exploiting the β5i S1 pocket has yielded selective inhibitors with anti-inflammatory and anti-myeloma activity (PMID:25006746, PMID:34228444, PMID:30279279).

Mechanistic history

Synthesis pass · year-by-year structured walk · 24 steps
  1. 1993 High

    Established that this proteasome β-subunit is the catalytic component responsible for chymotrypsin-like activity, defining its core enzymatic identity.

    Evidence Genetic complementation and loss-of-function of the homologous yeast PRE2 gene with proteasome activity and ubiquitin-accumulation assays

    PMID:8383129

    Open questions at the time
    • Inference from yeast ortholog rather than direct human PSMB8 catalysis
    • Did not address immunoproteasome-specific cleavage preferences
  2. 1992 Medium

    Showed the proteasomal function of this subunit is essential for viability in yeast.

    Evidence Genomic disruption of the yeast homolog PRG1 showing lethality

    PMID:1452031

    Open questions at the time
    • Essentiality refers to yeast, not the IFN-γ-inducible human subunit
    • Single study
  3. 1993 High

    Defined PSMB8 as a proprotein that is N-terminally processed from ~30 kDa to a mature 23 kDa form before incorporation, establishing the maturation logic of the subunit.

    Evidence Pulse-chase, immunoprecipitation, and Western blot of proteasome preparations (two independent reports)

    PMID:8365398 PMID:8458375

    Open questions at the time
    • Did not identify the protease/mechanism of propeptide cleavage
    • Functional role of the propeptide not yet defined
  4. 1994 High

    Demonstrated that incorporation of PSMB8 raises proteasomal chymotrypsin- and trypsin-like activities in dose-dependent fashion and that assembly proceeds via precursor complexes with intra-precursor processing.

    Evidence Gene transfection with fluorogenic substrate kinetics; sedimentation and pulse-chase fractionation of precursor and mature complexes

    PMID:7937744 PMID:8120905

    Open questions at the time
    • Active-site residue not yet directly implicated
    • Substrate range limited to model fluorogenic peptides
  5. 1995 High

    Showed PSMB8 incorporation alters cleavage-site specificity and the quality of peptide products from defined polypeptides independent of IFN-γ and of PA28 selectivity, linking the subunit to antigenic peptide repertoire.

    Evidence Stable LMP transfection with in vitro digestion of a defined 25-mer, HPLC/mass spectrometry of products, and PA28 reconstitution

    PMID:7559557 PMID:7589133

    Open questions at the time
    • MHC class I presentation not yet directly measured
    • Cooperativity mechanism between subunits unresolved
  6. 1996 High

    Established that IFN-γ-induced activity changes arise from PSMB8 replacing the constitutive subunit X/β5c, via reciprocal gain/loss-of-function.

    Evidence Reciprocal transfection of subunit X and PSMB8 in HeLa cells with fluorogenic activity assays and stoichiometry immunoblots

    PMID:8663318

    Open questions at the time
    • Did not map structural basis of differential specificity
    • Whole-substrate consequences of subunit swap not assessed here
  7. 1997 High

    Confirmed PSMB8 is itself a catalytic subunit by direct active-site labeling.

    Evidence Radiolabeled active-site-directed inhibitor labeling of purified 20S/26S proteasomes with subunit identification by 2D-PAGE and immunoblot

    PMID:9312091

    Open questions at the time
    • Did not define which residue side-chains shape the S1 pocket
    • Relative contribution to trypsin- vs chymotrypsin-like activity not quantified
  8. 2000 High

    Resolved the propeptide's role in maturation—assisting incorporation efficiency but not strictly required—and placed POMP in precursor complexes only.

    Evidence Propeptide and active-site Thr mutagenesis with 2D gel/fractionation and POMP immunoblotting in T2 cells

    PMID:10926487

    Open questions at the time
    • Chaperone strength of the propeptide relative to β5 not yet compared
    • Active-site Thr role in catalysis vs incorporation only partly separated
  9. 2000 High

    Linked PSMB8-containing immunoproteasomes to enhanced MHC class I presentation of a defined epitope.

    Evidence Triple LMP transfection with CTL killing assay and in vitro epitope-precursor digestion analysis

    PMID:10878350

    Open questions at the time
    • Contribution of PSMB8 alone vs the triplet not isolated
    • Did not address presentation breadth genome-wide
  10. 2004 High

    Identified a viral strategy targeting PSMB8 maturation, showing HCV NS3 binds the propeptide region and reduces immunoproteasome peptidase activity.

    Evidence Yeast two-hybrid, in vitro binding, co-IP, domain mapping, and peptidase assays in HCV replicon cells

    PMID:15303969

    Open questions at the time
    • Mechanism by which propeptide binding lowers activity not defined
    • In vivo immune-evasion consequence not tested
  11. 2005 High

    Identified IRF-1 as the master transcriptional driver of IFN-γ-dependent PSMB8 and coordinate immunoproteasome subunit expression.

    Evidence Tet-inducible IRF-1, siRNA knockdown, IRF-1 knockout mice, and genomic binding-site mapping

    PMID:15907481

    Open questions at the time
    • Other cooperating transcription factors not delineated
    • Cell-type-specific regulation not addressed
  12. 2010 High

    Connected PSMB8 to NF-κB-driven mucosal inflammation, establishing an immune-effector role beyond antigen processing.

    Evidence lmp7-/- mice in DSS colitis with NF-κB, cytokine, and Th1/Th17 analyses, plus bortezomib replication

    PMID:20581238

    Open questions at the time
    • Direct molecular substrate linking PSMB8 to NF-κB not identified here
    • Bortezomib is non-selective
  13. 2010 High

    Identified PSMB8 mutations as causative for human autoinflammatory syndromes (JMP, Nakajo-Nishimura) by disrupting β5i structure, assembly, and proteolytic activity.

    Evidence Homozygosity/exome mapping, structural modeling, immunoproteasome activity and assembly assays, and cytokine measurements in patient cells; in vivo siRNA adipocyte studies

    PMID:21129723 PMID:21852578 PMID:21881205

    Open questions at the time
    • Precise substrate(s) whose mishandling drives cytokine elevation not defined
    • Adipocyte differentiation mechanism partly correlative
  14. 2011 High

    Demonstrated PSMB8 is protective in stressed tissue, clearing ubiquitinated aggregates and supporting NF-κB-dependent survival during viral myocarditis.

    Evidence β5i knockout mice in CVB3 myocarditis with aggregate, NF-κB, and apoptosis readouts and adoptive T cell transfer

    PMID:21909276

    Open questions at the time
    • Context-dependence of NF-κB outcomes (protective vs pathogenic) unresolved
    • Substrate underlying aggregate clearance not specified
  15. 2012 High

    Showed the PSMB8 propeptide is a superior maturation chaperone required for optimal MHC class I surface expression, mechanistically linking maturation efficiency to immune function.

    Evidence LMP7-deficient mouse infection, subunit integration assays, maturation kinetics, and MHC class I flow cytometry

    PMID:22768135

    Open questions at the time
    • Structural basis of enhanced chaperone activity not resolved
    • Quantitative contribution to total proteasome pool tissue-dependent
  16. 2012 High

    Defined a mechanism for PSMB8 control of T helper fate via STAT3/STAT1/SMAD phosphorylation balancing Th17/Th1 versus Treg.

    Evidence LMP7-/- and ONX 0914-treated CD4+ T cells under polarizing conditions with phospho-immunoblots and in vivo colitis models

    PMID:22984077

    Open questions at the time
    • Direct proteasomal substrate controlling STAT phosphorylation not identified
    • ONX 0914 selectivity caveat (see 2018 finding)
  17. 2014 High

    Provided the structural basis for selective β5i inhibition by exploiting S1-pocket differences between β5c and β5i.

    Evidence X-ray crystallography of constitutive and immunoproteasome 20S cores with inhibitor selectivity profiling

    PMID:25006746

    Open questions at the time
    • Did not address in vivo target engagement or off-subunit effects at higher exposure
    • Structure of human β5i not the species crystallized
  18. 2018 High

    Localized a non-hematopoietic PSMB8 requirement in thymic stromal cells preventing excessive negative selection, refining its role in T cell repertoire shaping.

    Evidence LMP7 KO mice with LCMV infection, bone marrow chimeras, adoptive transfer, and tetramer staining

    PMID:29067678

    Open questions at the time
    • Specific self-peptides altered by PSMB8 loss not identified
    • mTEC identity inferred
  19. 2018 Medium

    Implicated PSMB8 in neurodegenerative protein aggregation, showing increased immunoproteasome activity that degrades α-synuclein aggregates.

    Evidence Quantitative proteomics and activity assays in α-synuclein mouse model and human PD/DLB brain with aggregate degradation assay

    PMID:29759483

    Open questions at the time
    • Causal versus reactive role of PSMB8 upregulation unresolved
    • Single-lab observation
  20. 2018 Medium

    Linked PSMB8 to podocyte EMT via IκB/NF-κB/TGF-β signaling in diabetic kidney, downstream of apelin.

    Evidence β5i KO mice with apelin treatment and IκB/NF-κB/TGF-β/Smad pathway analyses

    PMID:30301930

    Open questions at the time
    • Direct PSMB8 substrate in this axis not identified
    • Single lab
  21. 2019 High

    Identified specific PSMB8 degradation substrates (ATG5, ATRAP, PTEN) explaining its role in autophagy suppression, AT1R signaling, and cardiovascular remodeling.

    Evidence β5i KO and overexpression mice across hypertrophy/AF/retinopathy/hypertension models with Co-IP, degradation assays, and substrate-rescue epistasis

    PMID:30571551 PMID:31086810 PMID:31629736 PMID:31636038

    Open questions at the time
    • How an immunoproteasome subunit acquires substrate specificity for these targets mechanistically unclear
    • Co-IP-based interactions without structural detail
  22. 2020 Medium

    Extended PSMB8's NF-κB-coupled disease role to atherosclerosis (MERTK/efferocytosis) and aortic aneurysm (NLRP3 pyroptosis).

    Evidence β5i/Apoe double KO, bone marrow chimeras, and PR-957 in atherosclerosis and AAA models with efferocytosis and pyroptosis readouts

    PMID:31758542 PMID:33019975

    Open questions at the time
    • MERTK regulation is transcriptional (via NF-κB) rather than direct degradation
    • AAA finding single lab
  23. 2021 High

    Advanced selective PSMB8 inhibitors as therapeutics, including an oral agent active against multiple myeloma, and clarified that dual β5i/β2i inhibition underlies some immunomodulatory efficacy.

    Evidence Structure-based inhibitor design (M3258) with myeloma xenografts; comparison of selective PRN1126 vs ONX 0914 in colitis/EAE

    PMID:30279279 PMID:34228444

    Open questions at the time
    • Therapeutic window of pure β5i inhibition in autoinflammation uncertain
    • Long-term safety of immunoproteasome inhibition not addressed
  24. 2022 Medium

    Placed PSMB8 in a PERK/NF-κB neuroinflammatory axis in manganese-exposed microglia.

    Evidence In vivo Mn exposure and BV2 cells with selective PSMB8 and PERK inhibitors and NF-κB analysis

    PMID:35378207

    Open questions at the time
    • Direct substrate connecting PERK to PSMB8 to NF-κB not identified
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how an immunoproteasome catalytic subunit achieves selective targeting of individual substrates (ATG5, ATRAP, PTEN) and tilts NF-κB outcomes in a tissue-specific, sometimes opposing (protective vs pathogenic), manner.
  • Structural/biochemical basis of substrate selectivity beyond bulk proteolysis unknown
  • Mechanism switching PSMB8 between protective aggregate-clearance and pathogenic substrate degradation undefined
  • Direct degradation versus indirect transcriptional effects not always distinguished

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 4 GO:0016787 hydrolase activity 3 GO:0044183 protein folding chaperone 2
Localization
GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-168256 Immune System 4 R-HSA-392499 Metabolism of proteins 3
Partners
ATG5ATRAPIRF1POMPPSMB9PTEN
Complex memberships
16S immunoproteasome precursor complex20S immunoproteasome20S proteasome core particle

Evidence

Reading pass · 35 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1993 The yeast PRE2 gene (highly homologous to human RING10/PSMB8, 60% identity) encodes a proteasome beta-subunit whose loss abolishes chymotrypsin-like activity of the 20S proteasome and causes accumulation of ubiquitinated proteins, establishing that this subunit is the catalytic component responsible for chymotryptic activity. Genetic complementation of pre2 mutants, missense mutation identification, biochemical assay of proteasome chymotryptic activity, ubiquitinated protein accumulation assay The Journal of biological chemistry High 8383129
1992 A yeast homolog of RING10 (PSMB8), PRG1, is essential for cell viability, indicating that the proteasome function of this subunit is required for basic cellular processes. Genomic disruption of PRG1 in yeast showing lethality Gene Medium 1452031
1993 LMP7 (PSMB8) is synthesized as a proprotein (~30 kDa) and undergoes post-translational N-terminal cleavage to yield the mature 23 kDa subunit that is incorporated into the 20S proteasome complex. Pulse-chase experiments, Western blot, anti-proteasome and anti-LMP7 immunoprecipitation European journal of biochemistry High 8365398 8458375
1993 LMP7 protein undergoes post-translational cleavage of its N-terminus (pro-sequence) before incorporation into the proteasome, reducing from predicted ~30 kDa to 23 kDa; the cleaved form is the active proteasome subunit. Western blot of anti-proteasome immunoprecipitates, pulse-chase analysis European journal of immunology High 8458375
1994 LMP7 (PSMB8) transfection into lymphoblasts or HeLa cells increases the Vmax of 20S and 26S proteasomes for cleavage after hydrophobic and basic residues (chymotrypsin-like and trypsin-like activities) without affecting hydrolysis after acidic residues; the magnitude of activity change is proportional to the amount of LMP7 incorporated. Gene transfection, fluorogenic peptide substrate assays of isolated 20S and 26S proteasomes Proceedings of the National Academy of Sciences of the United States of America High 7937744
1994 LMP7 (PSMB8) and LMP2 are assembled into 20S proteasomes via 13-16S precursor complexes; pro-proteins of both subunits are processed within these preproteasome intermediates, and only the processed forms are part of active 20S proteasomes. Sedimentation analysis, pulse-chase labeling, immunoblotting of precursor and mature proteasome fractions Journal of molecular biology High 8120905
1995 Incorporation of LMP7 (with or without LMP2) into 20S proteasomes alters cleavage site preference and changes the quality of peptide products generated from a defined polypeptide substrate (CMV IE pp89 25-mer), independently of IFN-gamma stimulation; both subunits together induce a drastic increase in positive cooperativity (Hill coefficient) between proteasome subunits. Stable transfection of LMP subunits, in vitro digestion of defined polypeptide, HPLC and mass spectrometry of cleavage products, fluorogenic substrate kinetics European journal of immunology High 7589133
1995 The IFN-gamma-inducible 11S regulator (PA28) does not preferentially activate LMP7-containing proteasomes, but binding of PA28 to any proteasome preparation markedly changes the quality and quantity of peptide products; LMP7 content determines the cleavage product profile independently of PA28. Transfection of LMP subunits, in vitro 25-mer digestion with and without purified PA28, HPLC and electrospray mass spectrometry The Journal of biological chemistry High 7559557
1996 LMP7 (PSMB8) replaces the constitutive subunit X (epsilon/β5c) upon IFN-gamma treatment; overexpression of X reduces hydrolysis after hydrophobic and basic residues—effects opposite to LMP7 transfection—demonstrating that loss of X contributes to the increased chymotryptic/tryptic activities seen after IFN-gamma induction. Gene transfection of subunit X into HeLa cells, fluorogenic peptide substrate assays, immunoblot quantification of subunit stoichiometry The Journal of biological chemistry High 8663318
1997 LMP7 (PSMB8) is covalently labeled by active-site-directed radiolabeled chloromethane and diazomethane inhibitors of chymotrypsin-like activity, establishing LMP7 as a catalytic subunit that contributes to both trypsin-like and chymotrypsin-like proteasomal activities. Radiolabeled active-site inhibitor labeling of purified 20S and 26S proteasomes, RP-HPLC, SDS-PAGE, 2D-PAGE, immunoblotting with subunit-specific antibodies The Journal of biological chemistry High 9312091
2000 The human proteasome maturation protein POMP (Ump1 homolog) is found only in 16S precursor complexes and not in mature 20S proteasomes; LMP7 propeptide deletion reduces incorporation efficiency and causes accumulation of precursor complexes with elevated POMP, indicating the propeptide assists maturation but is not strictly required for incorporation. An active-site threonine mutation does not affect LMP7 incorporation. 2D gel analysis, subcellular fractionation, Northern blot, mutagenesis of LMP7 propeptide and active-site Thr, immunoblotting of precursor fractions in T2 cells Journal of molecular biology High 10926487
2000 Overexpression of LMP2, LMP7, and MECL-1 together (triple transfectants) in cells markedly enhances MHC class I-restricted presentation of the LCMV NP118 epitope; in vitro, immunoproteasomes generate higher amounts of 11- and 12-mer precursor fragments containing NP118 than constitutive proteasomes. PA28 overexpression does not produce a comparable enhancement. Triple transfection, CTL killing assay for antigen presentation, in vitro peptide digestion with HPLC analysis of products Journal of immunology High 10878350
2004 HCV NS3 protein directly interacts with the pro-sequence region (amino acids 1-40) of LMP7 via its protease domain (confirmed by yeast two-hybrid and in vitro binding and co-IP); this interaction does not affect NS3 protease activity in vitro, but cells stably replicating HCV subgenomic replicon show markedly reduced LMP7 immunoproteasome peptidase activities. Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation, domain mapping, fluorogenic peptidase activity assay in HCV replicon cell line The Biochemical journal High 15303969
2005 IRF-1 is required for IFN-gamma-dependent LMP7 transcription; a tetracycline-inducible IRF-1 system induces LMP7 expression, a specific IRF-1-binding genomic region in the LMP7 locus was identified, and IRF-1 knockdown by siRNA as well as IRF-1-/- mice confirmed that IRF-1 is the master transcriptional regulator driving concerted immunoproteasome subunit expression. Tet-inducible IRF-1 expression, siRNA knockdown, IRF-1 knockout mice, genomic footprinting/reporter assay to map IRF-1 binding region FEBS letters High 15907481
2010 LMP7 (PSMB8) deficiency in mice results in significantly attenuated dextran sodium sulfate-induced colitis due to reduced NF-κB signaling; this is mechanistically linked to reduced secretion of proinflammatory cytokines and chemokines, decreased neutrophil infiltration, and diminished Th1/Th17 expansion. lmp7-/- mouse model, DSS colitis induction, NF-κB pathway analysis, cytokine/chemokine measurement, histological analysis Gut High 20581238
2010 A homozygous missense mutation (Thr75Met) in PSMB8 causes JMP syndrome; the mutation disrupts the tertiary structure of β5i and results in significantly reduced chymotrypsin-like proteolytic activity of immunoproteasomes in patient lymphoblasts compared to normal cells. Homozygosity mapping, direct sequencing, structural modeling, immunoproteasome chymotryptic activity assay in patient vs. normal lymphoblasts American journal of human genetics High 21129723
2011 A G201V mutation in PSMB8 (β5i) in Nakajo-Nishimura syndrome disrupts the β-sheet structure near the catalytic threonine, prevents efficient incorporation of β5i into immunoproteasome precursors, reduces total proteasome activity, and causes accumulation of ubiquitinated and oxidized proteins; this leads to increased IL-6 and IP-10 secretion and elevated p38 phosphorylation. Structural analysis (mutation position modeling), immunoproteasome assembly assay, proteasome activity assay, ubiquitinated/oxidized protein accumulation assay, cytokine ELISA, phospho-p38 immunoblot in patient cells Proceedings of the National Academy of Sciences of the United States of America High 21852578
2011 A G197V mutation in PSMB8 increases assembly intermediates of immunoproteasomes, decreases proteasome function, causes ubiquitin-coupled protein accumulation, and leads to increased IL-6 expression in patient skin and B cells; PSMB8 knockdown inhibits murine and human adipocyte differentiation in vitro, and siRNA injection against Psmb8 in mouse skin reduces adipocyte tissue volume. Exome sequencing, proteasome activity assay, ubiquitin accumulation immunoblot, siRNA knockdown of Psmb8 in mouse skin/adipocyte differentiation assay The Journal of clinical investigation High 21881205
2011 β5i/LMP7 deficiency in mice leads to impaired immunoproteasome function, failure to clear poly-ubiquitinated protein aggregates in cytokine-stressed cardiomyocytes during CVB3 myocarditis, impaired NF-κB activation, and increased apoptotic cell death, resulting in exacerbated acute myocardial damage despite identical viral load. β5i/LMP7 knockout mice, CVB3 infection model, ubiquitinated aggregate detection, NF-κB activation assay, apoptosis quantification, adoptive T cell transfer PLoS pathogens High 21909276
2012 LMP7 propeptide (proLMP7) shows significantly higher chaperone activity than the β5 propeptide (proβ5) in promoting proteasome maturation; proLMP7 promotes integration of both immunosubunits and mixed proteasomes, and increased efficiency of proteasome maturation by proLMP7 is required for optimal MHC class I surface expression. LMP7 induction also increases total proteasome abundance in infected tissue. LMP7-deficient mouse infection model, IFNγ stimulation experiments, subunit integration assays, proteasome maturation kinetics, MHC class I surface expression by flow cytometry PloS one High 22768135
2012 LMP7 deficiency or selective inhibition suppresses Th17 and Th1 differentiation while promoting regulatory T cell (Treg) development; mechanistically, LMP7 inhibition blocks STAT3 phosphorylation in developing Th17 cells and enhances SMAD phosphorylation in Tregs, and reduces STAT1 phosphorylation in Th1 cells. LMP7-/- CD4+ T cells and ONX 0914-treated WT T cells under polarizing conditions, phospho-STAT3/SMAD/STAT1 immunoblot, DSS colitis and T cell transfer colitis models in vivo Journal of immunology High 22984077
2014 X-ray crystal structures of murine constitutive and immunoproteasome 20S core particles informed rational design of β5i (LMP7)-selective inhibitors; structural differences in the S1 pocket between β5c and β5i were exploited to achieve cell-permeable inhibitors with high selectivity. Structure-based drug design using X-ray crystallography of 20S proteasome complexes, selectivity profiling across all proteasome subunits Journal of medicinal chemistry High 25006746
2016 miR-451 directly targets LMP7 (PSMB8) 3′UTR to suppress LMP7 expression, thereby inhibiting NF-κB activity and reducing proinflammatory cytokine transcription in mesangial cells; in db/db diabetic mice, increasing miR-451 inhibited LMP7/NF-κB and attenuated glomerular injury. Deep sequencing, dual-luciferase reporter assay, Western blot, chromatin immunoprecipitation, in vivo miR-451 overexpression in db/db mice Molecular and cellular endocrinology High 27264074
2018 Co-inhibition of both LMP7 and LMP2 (but not LMP7 alone) is required to impair MHC class I surface expression, suppress IL-6 secretion, block Th17 differentiation, and strongly ameliorate experimental colitis and EAE; prolonged ONX 0914 exposure inhibits both subunits, explaining its efficacy. Selective LMP7 inhibitor PRN1126 vs. ONX 0914 comparison, LMP2+LMP7 dual inhibitor combination, DSS colitis, EAE models, IL-6 ELISA, MHC class I flow cytometry EMBO reports High 30279279
2019 β5i (PSMB8) interacts with ATG5, promoting its degradation, thereby inhibiting autophagy and driving pathological cardiac hypertrophy; β5i knockout attenuates hypertrophy, and ATG5 knockdown or autophagy inhibition reverses the β5i-KO protection. β5i KO and transgenic overexpression mice, Ang II-induced hypertrophy model, Co-IP (β5i–ATG5 interaction), ATG5 degradation assay, autophagic flux assays, genetic epistasis (ATG5 KD + β5i KO) Science advances High 31086810
2019 β5i (PSMB8) promotes ATRAP (AT1R-associated protein) degradation in atrial tissue; β5i upregulation by Ang II leads to ATRAP degradation, resulting in AT1R-mediated NF-κB activation, increased NADPH oxidase activity, TGF-β1/Smad signaling, and altered ion channel expression (Kir2.1, CX43), thereby driving atrial fibrillation. β5i KO and AAV9-β5i overexpression mice, Ang II infusion AF model, ATRAP co-IP and degradation assay, ATRAP overexpression rescue, NF-κB and TGF-β pathway assays Hypertension High 30571551
2019 β5i (PSMB8) promotes ATRAP degradation in the retina; β5i KO restores Ang II-induced downregulation of ATRAP and attenuates AT1R-mediated downstream signaling, thereby reducing hypertensive retinopathy, while adenoviral β5i overexpression aggravates the phenotype. β5i KO and Ad-β5i overexpression mice, Ang II infusion retinopathy model, ATRAP degradation assay, AT1R downstream signaling analysis, ATRAP overexpression rescue Molecular therapy High 31636038
2019 β5i (PSMB8) promotes PTEN degradation in DOCA-salt hypertensive hearts; β5i KO attenuates cardiac remodeling by restoring PTEN levels, and PTEN blockade reverses the protective effects of β5i KO, placing PTEN as a key substrate whose stability is regulated by β5i-dependent proteasomal degradation. β5i KO mice and PR-957 pharmacological inhibition, DOCA-salt hypertension model, PTEN degradation assay, AKT/mTOR/TGF-β/NF-κB pathway analysis, VO-OHpic rescue experiment Journal of molecular and cellular cardiology High 31629736
2020 β5i (PSMB8) promotes atherosclerosis by targeting MERTK for degradation via NF-κB-dependent suppression of Mertk transcription; β5i deletion reduces IκBα degradation, inhibits NF-κB, increases MERTK expression, and enhances efferocytosis of apoptotic cells in atherosclerotic lesions. β5i/Apoe double KO mice, bone marrow transplantation, ATD-fed mouse atherosclerosis model, efferocytosis assay, MERTK expression, IκBα/NF-κB pathway analysis, PR-957 pharmacological treatment The Journal of pathology High 31758542
2020 β5i (PSMB8) promotes macrophage pyroptosis during abdominal aortic aneurysm formation via activation of NF-κB and upregulation of NLRP3; β5i inhibition or knockout decreases macrophage pyroptosis and AAA severity through the IκB/NF-κB pathway. β5i KO mice, PR-957 treatment, AAA mouse model, pyroptosis markers in tissue and BMDMs, OXLDL stimulation, NF-κB/NLRP3 pathway analysis Biochemical and biophysical research communications Medium 33019975
2021 M3258, an orally bioavailable, reversible, highly selective LMP7 (β5i) inhibitor, was developed through structure-based optimization using X-ray crystal structures; it demonstrates potent suppression of LMP7 activity, ubiquitinated protein turnover, and induces apoptosis in multiple myeloma cells in vitro and in vivo. Structure-based drug design (X-ray crystallography), selectivity profiling, multiple myeloma xenograft models, ubiquitin turnover assay, apoptosis assay Journal of medicinal chemistry High 34228444
2018 Lmp7 (PSMB8) levels and activity are significantly increased in a mouse model of α-synuclein aggregation and in post-mortem human PD and dementia with Lewy bodies brains; the immunoproteasome degrades α-synuclein aggregates and generates potentially antigenic peptides from them. Quantitative proteomics (6215 proteins), immunoproteasome activity assay in mouse model and human post-mortem tissue, α-synuclein aggregate degradation assay EBioMedicine Medium 29759483
2017 LMP7 is required in radioresistant thymic cells (likely mTECs) to prevent excessive negative selection of GP118-125-specific T cell precursors; LMP7-deficient mice completely lack GP118-125-specific CD8+ T cells, which is restored by bone marrow chimeras showing LMP7 requirement in non-hematopoietic cells. LMP7 KO mice, LCMV infection model, bone marrow chimera generation, adoptive transfer of LMP7-deficient CD8+ T cells into RAG1-/- mice, tetramer staining European journal of immunology High 29067678
2022 PSMB8 (β5i) expression is upregulated in manganese-exposed microglia via PERK signaling; selective PSMB8 inhibition reduces neuroinflammation (TNF-α, iNOS, CCL12 production, microglial activation) and inhibition of PSMB8 reduces NF-κB p65 phosphorylation, placing PSMB8 in a PERK/NF-κB signaling axis during Mn neurotoxicity. In vivo Mn exposure mouse model, BV2 cell culture, selective PSMB8 inhibitor treatment, PERK inhibitor, NF-κB pathway analysis, learning/memory tests, Golgi staining Food and chemical toxicology Medium 35378207
2018 Apelin inhibits epithelial-mesenchymal transition (EMT) of podocytes in diabetic mice through downregulation of β5i expression; β5i KO mice confirmed the dependence of apelin's anti-EMT effect on β5i; mechanistically, apelin decreases β5i expression, which reduces degradation of pIκB, promotes IκB nuclear translocation, inhibits NF-κB-driven TGF-β expression, and decreases Smad pathway activation. β5i KO mice, diabetic mouse model, apelin treatment, pIκB degradation assay, IκB localization, TGF-β/Smad pathway analysis Cell death & disease Medium 30301930

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1994 Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proceedings of the National Academy of Sciences of the United States of America 277 7937744
2010 PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. American journal of human genetics 254 21129723
2011 Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proceedings of the National Academy of Sciences of the United States of America 241 21852578
1993 PRE2, highly homologous to the human major histocompatibility complex-linked RING10 gene, codes for a yeast proteasome subunit necessary for chrymotryptic activity and degradation of ubiquitinated proteins. The Journal of biological chemistry 235 8383129
2011 A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. The Journal of clinical investigation 234 21881205
1995 The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. The Journal of biological chemistry 202 7559557
2010 Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 149 20581238
2020 LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. Journal of experimental & clinical cancer research : CR 141 32891166
1995 Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. European journal of immunology 141 7589133
2012 Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. Journal of immunology (Baltimore, Md. : 1950) 132 22984077
1994 20 S proteasomes are assembled via distinct precursor complexes. Processing of LMP2 and LMP7 proproteins takes place in 13-16 S preproteasome complexes. Journal of molecular biology 129 8120905
2003 Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue antigens 127 12694570
1996 Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. The Journal of biological chemistry 126 8663318
2016 miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy. Molecular and cellular endocrinology 103 27264074
2000 Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes. Journal of molecular biology 103 10926487
2000 Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. Journal of immunology (Baltimore, Md. : 1950) 96 10878350
1995 Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. American journal of human genetics 91 7847389
2014 Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. Journal of medicinal chemistry 83 25006746
2019 The immunoproteasome catalytic β5i subunit regulates cardiac hypertrophy by targeting the autophagy protein ATG5 for degradation. Science advances 82 31086810
2011 Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis. PLoS pathogens 81 21909276
1994 MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. Journal of immunology (Baltimore, Md. : 1950) 80 8301122
2005 LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 73 15774487
2018 Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO reports 68 30279279
2006 T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens. Journal of immunology (Baltimore, Md. : 1950) 66 16547243
2015 Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis research & therapy 65 25889472
1993 The major-histocompatibility-complex-encoded beta-type proteasome subunits LMP2 and LMP7. Evidence that LMP2 and LMP7 are synthesized as proproteins and that cellular levels of both mRNA and LMP-containing 20S proteasomes are differentially regulated. European journal of biochemistry 61 8365398
1998 Expression of MHC class Ia and class Ib during ontogeny: high expression in epithelia and coregulation of class Ia and lmp7 genes. Journal of immunology (Baltimore, Md. : 1950) 58 9510188
2023 LncRNA PSMB8-AS1 Instigates Vascular Inflammation to Aggravate Atherosclerosis. Circulation research 57 38084631
2019 Immunoproteasome Subunit β5i Promotes Ang II (Angiotensin II)-Induced Atrial Fibrillation by Targeting ATRAP (Ang II Type I Receptor-Associated Protein) Degradation in Mice. Hypertension (Dallas, Tex. : 1979) 55 30571551
2006 Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome. Arthritis and rheumatism 55 16646031
1997 Catalytic properties of 26 S and 20 S proteasomes and radiolabeling of MB1, LMP7, and C7 subunits associated with trypsin-like and chymotrypsin-like activities. The Journal of biological chemistry 55 9312091
2017 Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget 53 28881574
2019 Long non-coding RNA PSMB8-AS1 regulates influenza virus replication. RNA biology 52 30669933
2010 PSMB8 (LMP7) but not PSMB9 (LMP2) gene polymorphisms are associated to pigeon breeder's hypersensitivity pneumonitis. Respiratory medicine 44 20153157
1995 Isolation of Xenopus LMP-7 homologues. Striking allelic diversity and linkage to MHC. Journal of immunology (Baltimore, Md. : 1950) 44 7636247
1993 The major histocompatibility complex-encoded proteasome component LMP7: alternative first exons and post-translational processing. European journal of immunology 42 8458375
2018 PSMB8 regulates glioma cell migration, proliferation, and apoptosis through modulating ERK1/2 and PI3K/AKT signaling pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 39 29428669
2004 Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. The Biochemical journal 39 15303969
2018 Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders. EBioMedicine 38 29759483
2005 IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome. FEBS letters 38 15907481
1994 Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells. European journal of immunology 38 8056044
1993 Genomic organization and tissue expression of the mouse proteasome gene Lmp-7. Immunogenetics 38 8406612
2019 miR-451a inhibits cancer growth, epithelial-mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8. Journal of cellular and molecular medicine 37 31559672
2015 Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis. European journal of immunology 35 26464284
2021 M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models. Molecular cancer therapeutics 33 34045234
2017 PSMB8 as a Candidate Marker of Responsiveness to Preoperative Radiation Therapy in Rectal Cancer Patients. International journal of radiation oncology, biology, physics 33 28721901
2015 The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy. Brain, behavior, and immunity 32 26044087
2011 The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer research 32 22037870
2018 Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers. Cancer research and treatment 31 29510614
2006 Heat shock up-regulates lmp2 and lmp7 and enhances presentation of immunoproteasome-dependent epitopes. Journal of immunology (Baltimore, Md. : 1950) 31 17142736
1995 Differences in catalytic activities and subunit pattern of multicatalytic proteinase complexes (proteasomes) isolated from bovine pituitary, lung, and liver. Changes in LMP7 and the component necessary for expression of the chymotrypsin-like activity. The Journal of biological chemistry 31 7673255
2021 Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i). Journal of medicinal chemistry 30 34228444
2019 Ablation of Immunoproteasome β5i Subunit Suppresses Hypertensive Retinopathy by Blocking ATRAP Degradation in Mice. Molecular therapy : the journal of the American Society of Gene Therapy 30 31636038
2000 Trans-species polymorphism of the major histocompatibility complex-encoded proteasome subunit LMP7 in an amphibian genus, Xenopus. Immunogenetics 30 10752627
1992 cDNA cloning of rat proteasome subunit RC1, a homologue of RING10 located in the human MHC class II region. FEBS letters 30 1451788
2019 PSMB8-AS1 activated by ELK1 promotes cell proliferation in glioma via regulating miR-574-5p/RAB10. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 29 31812014
1997 No independent associations of LMP2 and LMP7 polymorphisms with susceptibility to develop IDDM. Diabetes 29 9000709
2019 Ablation and Inhibition of the Immunoproteasome Catalytic Subunit LMP7 Attenuate Experimental Abdominal Aortic Aneurysm Formation in Mice. Journal of immunology (Baltimore, Md. : 1950) 28 30642978
2015 Immunoproteasome subunit LMP7 Deficiency Improves Obesity and Metabolic Disorders. Scientific reports 28 26515636
2020 miR-451a is downregulated and targets PSMB8 in prostate cancer. The Kaohsiung journal of medical sciences 27 32128987
2018 Apelin inhibited epithelial-mesenchymal transition of podocytes in diabetic mice through downregulating immunoproteasome subunits β5i. Cell death & disease 27 30301930
2016 Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors. ChemMedChem 27 27561172
2020 PSMB8 inhibition decreases tumor angiogenesis in glioblastoma through vascular endothelial growth factor A reduction. Cancer science 26 32816328
2020 LncRNA PSMB8-AS1 acts as ceRNA of miR-22-3p to regulate DDIT4 expression in glioblastoma. Neuroscience letters 25 32151711
2019 Genetic ablation and pharmacological inhibition of immunosubunit β5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice. Journal of molecular and cellular cardiology 25 31629736
2017 A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat. PloS one 25 28700671
2022 Immunoproteasome subunit PSMB8 regulates microglia-mediated neuroinflammation upon manganese exposure by PERK signaling. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 23 35378207
2003 Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma research 23 12883363
2023 Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers. Scientific reports 22 36746983
2020 Immunoproteasome subunit β5i regulates diet-induced atherosclerosis through altering MERTK-mediated efferocytosis in Apoe knockout mice. The Journal of pathology 22 31758542
2017 The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire. European journal of immunology 22 29067678
2001 Polymorphism in the MHC-encoded LMP7 gene: association with JRA without functional significance for immunoproteasome assembly. The Journal of rheumatology 22 11669176
2000 Control of LMP7 expression in human endothelial cells by cytokines regulating cellular and humoral immunity. Cytokine 22 10975991
2000 Up-regulation of the proteasome subunit LMP7 in tissues of endotoxemic rats. The Journal of laboratory and clinical medicine 21 10779048
2020 Ageing-related changes in the levels of β-catenin, CacyBP/SIP, galectin-3 and immunoproteasome subunit LMP7 in the heart of men. PloS one 20 32119722
2019 LncRNA HCP5 promotes LAML progression via PSMB8-mediated PI3K/AKT pathway activation. Naunyn-Schmiedeberg's archives of pharmacology 20 31836918
2012 The proteasome system in infection: impact of β5 and LMP7 on composition, maturation and quantity of active proteasome complexes. PloS one 20 22768135
2002 LMP2 and LMP7 gene polymorphism in Mexican populations: Mestizos and Amerindians. Genes and immunity 20 12209365
2022 shRNA‑mediated knockdown of KNTC1 inhibits non-small-cell lung cancer through regulating PSMB8. Cell death & disease 19 35933405
2012 Long-lived dichotomous lineages of the proteasome subunit beta type 8 (PSMB8) gene surviving more than 500 million years as alleles or paralogs. Molecular biology and evolution 19 22491037
2023 HOXD9/miR-451a/PSMB8 axis is implicated in the regulation of cell proliferation and metastasis via PI3K/AKT signaling pathway in human anaplastic thyroid carcinoma. Journal of translational medicine 18 37974228
2021 Emodin alleviates high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation of mesangial cells by the circ_0000064/miR-30c-5p/Lmp7 axis. Journal of receptor and signal transduction research 18 34151713
2015 Association between LMP2 and LMP7 gene polymorphisms and the risk of gastric cancer: A case-control study. Oncology letters 18 26171060
2013 A new infant case of Nakajo-Nishimura syndrome with a genetic mutation in the immunoproteasome subunit: an overlapping entity with JMP and CANDLE syndrome related to PSMB8 mutations. Dermatology (Basel, Switzerland) 18 23942189
2017 Immunoproteasome subunit ß5i/LMP7-deficiency in atherosclerosis. Scientific reports 17 29042581
2021 The Immunoproteasome Subunits LMP2, LMP7 and MECL-1 Are Crucial Along the Induction of Cerebral Toxoplasmosis. Frontiers in immunology 16 33968021
2020 Macrophage pyroptosis is mediated by immunoproteasome subunit β5i (LMP7) in abdominal aortic aneurysm. Biochemical and biophysical research communications 16 33019975
2020 Comparative Assessment of the WNT/β-Catenin Pathway, CacyBP/SIP, and the Immunoproteasome Subunit LMP7 in Various Histological Types of Renal Cell Carcinoma. Frontiers in oncology 16 33330038
2015 Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft-versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen-Disparate Murine Model. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 16 26093043
2004 Expression of proteasome subunits low molecular mass polypeptide (LMP) 2 and LMP7 in the endometrium and placenta of rhesus monkey (Macaca mulatta) during early pregnancy. Biology of reproduction 16 15201202
2020 Selective Inhibition of the Immunoproteasome β5i Prevents PTEN Degradation and Attenuates Cardiac Hypertrophy. Frontiers in pharmacology 15 32595507
1992 A homolog of the proteasome-related RING10 gene is essential for yeast cell growth. Gene 15 1452031
2015 Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome. Translational oncology 14 25749172
2012 A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes. Pharmacology 14 22398747
2021 Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion. International journal of molecular sciences 13 33922041
2015 A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors. Angewandte Chemie (International ed. in English) 13 25973989
2021 Immunoproteasome impairment via β5i/LMP7-deletion leads to sustained pancreatic injury from experimental pancreatitis. Journal of cellular and molecular medicine 12 34132031
2020 Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides. Journal of medicinal chemistry 12 33095579
2013 Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing. Human immunology 12 24374040
2010 Transspecies dimorphic allelic lineages of the proteasome subunit beta-type 8 gene (PSMB8) in the teleost genus Oryzias. Proceedings of the National Academy of Sciences of the United States of America 12 21098669

Missed literature

Know a paper Affinage missed for PSMB8? Flag it for the maintainers and the community.

No submissions yet.